NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company specializing in the surgical diagnosis and treatment of neurological disorders, announced that it will release its financial results for the fiscal third quarter ended June 30, 2026, before market open on Thursday, August 13, 2026. The company will host an investor conference call and webcast at 8:30 a.m. Eastern time that same day to discuss the results, provide a corporate update, and answer questions from participants.
The upcoming earnings report is significant for the medical technology industry as NeuroOne continues to advance its minimally invasive electrode technology platform. The company has four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These products are designed to enhance surgical precision, potentially reducing hospitalization rates, surgical procedures, and overall healthcare costs while improving patient outcomes. The quarterly results will offer investors and healthcare professionals a closer look at the company's financial health and progress in commercializing these technologies.
In addition to its existing product lines, NeuroOne is actively engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. These initiatives could expand the company's addressable market and provide new therapeutic options for patients with chronic pain and other neurological conditions. The corporate update during the earnings call is expected to shed light on these R&D milestones and any strategic developments.
Investors and industry stakeholders are keen to see how NeuroOne's financial performance aligns with its growth trajectory. The company's focus on innovative solutions for neurological disorders positions it in a growing market where demand for minimally invasive procedures is rising. The earnings call will be accessible via a toll-free dial-in (888-506-0062) for U.S. participants and an international dial-in (973-528-0011) with access code 549778. A live webcast will also be available at [NMTC FY Q3 2026 Earnings Call Webcast](https://www.webcaster4.com/Webcast/Page/3001/54304).
For those unable to join live, a replay of the call will be available through August 27, 2026, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) with passcode 54304. Additionally, the webcast replay will be accessible via the same link until August 13, 2027.
The announcement comes at a time when the medical device industry is experiencing rapid innovation, particularly in neuromodulation and ablation technologies. NeuroOne's results could influence investor sentiment and market trends, given the company's focus on both diagnostic and therapeutic functions in a single platform. As the company continues to execute its strategy, the impact of these financial results will be closely monitored by those tracking advancements in neurological care.
